Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRS TenoBoost
- Development stage
- Preclinical
- Lead developer
- Peaches Biotech
01
Overview
PRS TenoBoost is a preclinical-stage allogeneic biological therapy being developed by Peaches Biotech for the treatment of tendon degeneration. The product is derived from the company's proprietary PRS (Selective Rich Plasma) platform, which utilizes a patented co-culture process involving M2 macrophages and tissue-specific cells (tenocytes) to generate a secretome rich in selective growth factors and immunomodulatory components. This therapy is designed to modulate the inflammatory environment and provide specific regenerative signals to support the repair of degenerate tendon tissue, representing a tissue-specific approach to regenerative medicine.
- Brand names
- PRS TenoBoost
- Other names
- PRS Teno BoostTenoBoost
Beyond the preview
Go deeper on PRS TenoBoost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRS TenoBoost.